Young-Kyoung Lee1,2, Byul A Jee3,2, So Mee Kwon3,2, Young-Sil Yoon1, Wei Guang Xu4, Hee-Jung Wang4, Xin Wei Wang5, Snorri S Thorgeirsson6, Jae-Seon Lee7, Hyun Goo Woo3,2, Gyesoon Yoon1,2. 1. Department of Biochemistry, Ajou University School of Medicine, Suwon, Korea. 2. Department of Biomedical Science, Graduate School, Ajou University, Suwon, Korea. 3. Department of Physiology, Ajou University School of Medicine, Suwon, Korea. 4. Department of Surgery, Ajou University School of Medicine, Suwon, Korea. 5. Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. 6. Laboratory of Experimental Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. 7. Department of Biomedical Sciences and Hypoxia-Related Disease Research Center, Inha University College of Medicine, Incheon, Korea.
Abstract
UNLABELLED: Many cancer cells require more glycolytic adenosine triphosphate production due to a mitochondrial respiratory defect. However, the roles of mitochondrial defects in cancer development and progression remain unclear. To address the role of transcriptomic regulation by mitochondrial defects in liver cancer cells, we performed gene expression profiling for three different cell models of mitochondrial defects: cells with chemical respiratory inhibition (rotenone, thenoyltrifluoroacetone, antimycin A, and oligomycin), cells with mitochondrial DNA depletion (Rho0), and liver cancer cells harboring mitochondrial defects (SNU354 and SNU423). By comparing gene expression in the three models, we identified 10 common mitochondrial defect-related genes that may be responsible for retrograde signaling from cancer cell mitochondria to the intracellular transcriptome. The concomitant expression of the 10 common mitochondrial defect genes is significantly associated with poor prognostic outcomes in liver cancers, suggesting their functional and clinical relevance. Among the common mitochondrial defect genes, we found that nuclear protein 1 (NUPR1) is one of the key transcription regulators. Knockdown of NUPR1 suppressed liver cancer cell invasion, which was mediated in a Ca(2+) signaling-dependent manner. In addition, by performing an NUPR1-centric network analysis and promoter binding assay, granulin was identified as a key downstream effector of NUPR1. We also report association of the NUPR1-granulin pathway with mitochondrial defect-derived glycolytic activation in human liver cancer. CONCLUSION: Mitochondrial respiratory defects and subsequent retrograde signaling, particularly the NUPR1-granulin pathway, play pivotal roles in liver cancer progression.
UNLABELLED: Many cancer cells require more glycolytic adenosine triphosphate production due to a mitochondrial respiratory defect. However, the roles of mitochondrial defects in cancer development and progression remain unclear. To address the role of transcriptomic regulation by mitochondrial defects in liver cancer cells, we performed gene expression profiling for three different cell models of mitochondrial defects: cells with chemical respiratory inhibition (rotenone, thenoyltrifluoroacetone, antimycin A, and oligomycin), cells with mitochondrial DNA depletion (Rho0), and liver cancer cells harboring mitochondrial defects (SNU354 and SNU423). By comparing gene expression in the three models, we identified 10 common mitochondrial defect-related genes that may be responsible for retrograde signaling from cancer cell mitochondria to the intracellular transcriptome. The concomitant expression of the 10 common mitochondrial defect genes is significantly associated with poor prognostic outcomes in liver cancers, suggesting their functional and clinical relevance. Among the common mitochondrial defect genes, we found that nuclear protein 1 (NUPR1) is one of the key transcription regulators. Knockdown of NUPR1 suppressed liver cancer cell invasion, which was mediated in a Ca(2+) signaling-dependent manner. In addition, by performing an NUPR1-centric network analysis and promoter binding assay, granulin was identified as a key downstream effector of NUPR1. We also report association of the NUPR1-granulin pathway with mitochondrial defect-derived glycolytic activation in humanliver cancer. CONCLUSION:Mitochondrial respiratory defects and subsequent retrograde signaling, particularly the NUPR1-granulin pathway, play pivotal roles in liver cancer progression.
Authors: Albrecht Hoffmeister; Alejandro Ropolo; Sophie Vasseur; Gustavo V Mallo; Hans Bodeker; Beate Ritz-Laser; Gregory R Dressler; Maria Ines Vaccaro; Jean-Charles Dagorn; Silvia Moreno; Juan Lucio Iovanna Journal: J Biol Chem Date: 2002-04-08 Impact factor: 5.157
Authors: Glynn Dennis; Brad T Sherman; Douglas A Hosack; Jun Yang; Wei Gao; H Clifford Lane; Richard A Lempicki Journal: Genome Biol Date: 2003-04-03 Impact factor: 13.583
Authors: A H Ree; M Tvermyr; O Engebraaten; M Rooman; O Røsok; E Hovig; L A Meza-Zepeda; O S Bruland; O Fodstad Journal: Cancer Res Date: 1999-09-15 Impact factor: 12.701
Authors: J A Encinar; G V Mallo; C Mizyrycki; L Giono; J M Gonzalez-Ros; M Rico; E Cánepa; S Moreno; J L Neira; J L Iovanna Journal: J Biol Chem Date: 2000-10-30 Impact factor: 5.157
Authors: José M Cuezva; Maryla Krajewska; Miguel López de Heredia; Stanislaw Krajewski; Gema Santamaría; Hoguen Kim; Juan M Zapata; Hiroyuki Marusawa; Margarita Chamorro; John C Reed Journal: Cancer Res Date: 2002-11-15 Impact factor: 12.701
Authors: M Nishikawa; S Nishiguchi; S Shiomi; A Tamori; N Koh; T Takeda; S Kubo; K Hirohashi; H Kinoshita; E Sato; M Inoue Journal: Cancer Res Date: 2001-03-01 Impact factor: 12.701
Authors: Robert Delsite; Sushant Kachhap; Ramaswamy Anbazhagan; Edward Gabrielson; Keshav K Singh Journal: Mol Cancer Date: 2002-11-12 Impact factor: 27.401
Authors: Kelsey L McLaughlin; Margaret A M Nelson; Hannah S Coalson; James T Hagen; McLane M Montgomery; Ashley R Wooten; Tonya N Zeczycki; Nasreen A Vohra; Kelsey H Fisher-Wellman Journal: Front Oncol Date: 2022-06-08 Impact factor: 5.738
Authors: Michaela Kripnerová; Hamendra Singh Parmar; Jiří Šána; Alena Kopková; Lenka Radová; Sieghart Sopper; Krzysztof Biernacki; Jan Jedlička; Michaela Kohoutová; Jitka Kuncová; Jan Peychl; Emil Rudolf; Miroslav Červinka; Zbyněk Houdek; Pavel Dvořák; Kateřina Houfková; Martin Pešta; Zdeněk Tůma; Martina Dolejšová; Filip Tichánek; Václav Babuška; Martin Leba; Ondřej Slabý; Jiří Hatina Journal: J Clin Med Date: 2021-05-25 Impact factor: 4.241
Authors: M R Emma; J L Iovanna; D Bachvarov; R Puleio; G R Loria; G Augello; S Candido; M Libra; A Gulino; V Cancila; J A McCubrey; G Montalto; M Cervello Journal: Cell Death Dis Date: 2016-06-23 Impact factor: 8.469
Authors: Minwoo Nam; Thomas E Akie; Masato Sanosaka; Siobhan M Craige; Shashi Kant; John F Keaney; Marcus P Cooper Journal: Sci Rep Date: 2017-05-17 Impact factor: 4.379